NICE’s diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) makes recommendations on tumour profiling tests for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer.
This guidance will assess use of the tests for ER-positive, HER2-negative cancer that has spread to the lymph nodes (LN-positive early breast cancer). DG34 will be withdrawn and replaced with new guidance which will include recommendations on tumour profiling tests for LN-positive early breast cancer and the existing recommendations on tumour profiling tests for LN-negative early breast cancer.
You can now comment on the diagnostics consultation document.
It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public.
Closing date for comments: 22 November 2023.
You can access the full information here.
